Rucaparib

Rucaparib

Names
IUPAC name 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Other names AG014699
Identifiers
CAS Registry Number	283173-50-2 Y
ChemSpider	8107584
InChI InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
Jmol-3D images	Image
KEGG	D10079 Y
PubChem	9931954
SMILES Fc4cc2c1c(nc(c1CCNC2=O)c3ccc(cc3)CNC)c4
Properties
Molecular formula	C19H18FN3O
Molar mass	323.36 g·mol−1
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Rucaparib (AG 014699) is a PARP inhibitor being investigated as a potential anti-cancer agent.

Rucaparib inhibits "the contraction of isolated vascular smooth muscle, including that from the tumours of cancer patients. It also reduces the migration of some cancer and normal cells in culture."^[1]

It can be taken orally in tablet form.^[2]

It has undergone phase I clinical trials for patients with advanced solid tumours.^[3] It is in phase II clinical trials for metastatic breast and ovarian cancer with known BRCA1 or BRCA2 mutation.^[4][2]

It is thought that 20% of women with ovarian cancer who are not BRCA positive might also benefit from PARP inhibitors. Clinical trials are beginning (as of April, 2014)

As of November 2012 four clinical trials of rucaparib were recruiting patients.^[5]

References